About This Webinar
Health plans are being asked to solve for total cost of care across a growing set of overlapping conditions — obesity, diabetes, hypertension, cholesterol, and multi-condition members at the intersection of all of them. GLP-1 utilization has intensified the pressure, surfacing sustainability questions that no single-condition vendor is positioned to answer on its own. This webinar reframes the payer conversation from vendor evaluation to partner strategy, focusing on how a multi-condition cardiometabolic care platform can plug into a plan’s own total-cost-of-care approach across multiple lines of business.
This conversation will explore what “partner, not vendor” looks like in practice for fully-insured, ASO, Medicare, Medicaid, and federal employee cohorts, and how plans can evaluate multi-condition care solutions on the terms that actually matter: cost defensibility, clinical efficacy their teams can stand behind, and a partnership model built on care across conditions, rather than single-condition vendors
Attendees Will Learn About
- Why the payer conversation has shifted from “add another vendor” to “better, deeper partnerships”
- What an anti-point-solution posture means for how plans evaluate cardiometabolic solutions
- Findings from Omada’s recently-published report that will highlight the value of structured, virtual cardiometabolic support, and what those findings may mean for a plan’s total-cost-of-care strategy
Presenters
Thomas Tsang, MD, MPH
Omada Health
Dr. Thomas Tsang is a clinician and healthcare executive with wide-ranging professional experience. Dr. Tsang was previously the founding CEO of Valera Health, a venture-backed tele-mental healthcare company. While there, he helped Valera grow from six to over 500 employees and earn recognition by Fast Company for innovation and impact. He also worked on the Affordable Care Act while serving…
Learn more about Thomas Tsang, MD, MPH
Melissa Cellucci
National Vice President of Health Plans
Omada Health
Learn more about Melissa Cellucci
